DYAI - Dyadic International Inc Year-over-year net earnings per share growth for the last 12 months

The biotechnological foundation of Dyadic International (DYAI) is resilient to economic downturns, as confirmed by the quarterly EPS trend, where the latest value is recorded as 2.10. This stability is driven by supplier diversification and the optimization of laboratory logistics. Technological superiority is guaranteed by patents for the C1 expression system, which enable the cost-effective and rapid synthesis of protein structures for major pharmaceutical partners.

dyadic.com (DYAI) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/11/2026

Analytical breakdowns for Dyadic International

- market value and analyst target forecast:

Price Chart dyadic.com|DYAI - Fair Value Consensus

- market capitalization statistics:

Market Valuation Dyadic|DYAI - Enterprise Value

- book capitalization indicators:

Net Assets per Single Share Dyadic International|DYAI - Book Valuation of Business|Market Capitalization to Book Value Ratio dyadic.com|DYAI - Total Business Assets

- debt and liquidity data:

- earnings and market multiples details:

DYAI - Net Income|Future Profit Dyadic International|DYAI - Company Value to Net Income|Forward P/E Multiple dyadic.com|DYAI - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dyadic|DYAI - Operating profit before amortization|Net earnings per share for the last 12 months Dyadic International|DYAI - Earnings per share for the last four quarters|Quarterly EPS earnings growth dyadic.com|DYAI - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Dyadic International

Initial company analysis:Dyadic International Inc - DYAI

Finished products of Dyadic International

To select fundamentally resilient assets, an investor must compare net profit dynamics with the company's market capitalization. This quarterly growth in earnings per share measures the rate of change in EPS, allowing for an assessment of the effectiveness of Dyadic International (DYAI) licensing alliances for C1 protein expression and the volatility of business returns through an analysis of this chart's trajectory.

Key competitors

Gilead Sciences (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara Corp - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth CureVac Pharma|Year-over-year earnings per share growth for the last twelve months Valneva SE (VALN)|Year-over-year net earnings per share change for the last twelve months vir.bio|Quarterly EPS earnings growth SIGA (SIGA Technologies)|EBS: Year-over-year earnings per share growth for the last 12 months|AVIR: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Invivyd, Inc.|ENTA: Quarterly EPS earnings growth|inovio.com (INO) - Quarterly EPS earnings growth|HLVX (HilleVax) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months KLRS (Kalaris Therapeutics Inc.)|Quarterly EPS earnings growth NNVC|Year-over-year net earnings per share change for the last twelve months Talphera Corporation|Quarterly EPS earnings growth COCP (Cocrystal Pharma, Inc.)|TRAW - Year-over-year net earnings per share growth for the last 12 months|DWTX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months QLGN (Qualigen Therapeutics Inc)|ALVR: Quarterly EPS earnings growth|VBIV - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Virios Therapeutics Inc.|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart Corp)